<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122457</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-1230</org_study_id>
    <nct_id>NCT03122457</nct_id>
  </id_info>
  <brief_title>Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide</brief_title>
  <official_title>Improvement of Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combination Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team plans to enroll a total of 40 subjects with self-reported perimenstrual acne.&#xD;
      Eligible women will be over the age of 18 and not on any current therapy. The patients will&#xD;
      first arrive for a screening visit, where they will be given questionnaires on acne quality&#xD;
      of life (acne QOL) and subjective assessments as well as flare ups (as used in the study by&#xD;
      Geller et al). The patients' skin will be assessed for inflammatory and non-inflammatory acne&#xD;
      vulgaris. The baseline visit (day 1) will be scheduled for one week prior to the first day of&#xD;
      menses (as studies indicate that most women have their acne flare during this time). The&#xD;
      study team will perform a zit count (counting papules, pustules, and comedones) and global&#xD;
      assessment, and the patient will be instructed to record their menses (which they will do for&#xD;
      the duration of the study). The patients will then return in 2 weeks, at day 15, and they&#xD;
      will be re-assessed. The patients will be dispensed the investigational product and&#xD;
      instructed on its daily use. The patients will continue to return every 14 days to have their&#xD;
      skin assessed until their final visit on day 99, one week after their 3rd menses on treatment&#xD;
      (4th menses on study). The duration of the study per patient is approximately 4 months, and&#xD;
      the study team anticipates an enrollment period of 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Application of clindamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel to treat perimenstrual acne</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PGA Score</measure>
    <time_frame>Day 99</time_frame>
    <description>Treatment Success defined as a score of 0 (clear) to 1 (almost clear) at day 99 (final study visit) by acne PGA scoring system. Full PGA scale from 0-5, with lower score indicating better drug efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Severity</measure>
    <time_frame>Day 99</time_frame>
    <description>Safety/drug-tolerance evaluated by subject-reported adverse events as well as physician evaluated erythema, scaling, drying, and stinging/burning on a 0-3 point scale, where 0=none and 3=severe.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination</intervention_name>
    <description>At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).</description>
    <arm_group_label>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18 years or older&#xD;
&#xD;
          -  Women who have had their first menses at least 12 months ago, and who currently have&#xD;
             regular menses.&#xD;
&#xD;
          -  Subjects must be able to read and understand English, and be able and willing to&#xD;
             complete the survey.&#xD;
&#xD;
          -  Subjects must have a self-reported complaint of peri-menstrual acne which has occurred&#xD;
             monthly for the last 6 months.&#xD;
&#xD;
          -  Subjects must be willing to forego any other therapy to the treatment area for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Subject is willing and able to participate in the study as an outpatient, making&#xD;
             frequent visits to the study center during the treatment and follow-up periods and to&#xD;
             comply with all study requirements including concomitant medication and other&#xD;
             treatment restrictions.&#xD;
&#xD;
          -  Subjects must have a negative urine pregnancy test result prior to study treatment&#xD;
             initiation and must agree to use an approved method of birth control while enrolled in&#xD;
             the study.&#xD;
&#xD;
          -  Subjects must be willing to use a form of birth control during the study. For the&#xD;
             purpose of this study, the following are considered acceptable methods of birth&#xD;
             control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g.,&#xD;
             condom and spermicide) and abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male subjects.&#xD;
&#xD;
          -  Post-menopausal women.&#xD;
&#xD;
          -  Women who do not suffer from acne.&#xD;
&#xD;
          -  Subjects who are allergic to clindamycin, benzoyl peroxide, lidocaine or any other&#xD;
             ingredients listed in the study medication.&#xD;
&#xD;
          -  Subjects with an unstable medical condition as deemed by the clinical investigator.&#xD;
&#xD;
          -  Subjects with ulcerative colitis or Crohn's disease.&#xD;
&#xD;
          -  Subjects with any dermatologic disease in the treatment area that may be exacerbated&#xD;
             by the treatment proposed or that might impair the evaluation of acne.&#xD;
&#xD;
          -  Women who are pregnant, lactating, or planning to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          -  Subjects who have used any topical prescription medications on the study area within&#xD;
             30 days prior to Visit 2 / Baseline.&#xD;
&#xD;
          -  Subjects on a stable dose of oral contraceptives for less than 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjali Shroff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Anjali Vekaria</investigator_full_name>
    <investigator_title>Chief Resident</investigator_title>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>C 1027</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 22, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03122457/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from July 2015 through August 2019 Please confirm the date of the first enrollment (month, day, year) Please confirm the date of the last study visit or the last date that data was collected (month, day, year)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lidamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combo</title>
          <description>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combo</title>
          <description>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PGA Score</title>
        <description>Treatment Success defined as a score of 0 (clear) to 1 (almost clear) at day 99 (final study visit) by acne PGA scoring system. Full PGA scale from 0-5, with lower score indicating better drug efficacy</description>
        <time_frame>Day 99</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combo</title>
            <description>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days</description>
          </group>
        </group_list>
        <measure>
          <title>PGA Score</title>
          <description>Treatment Success defined as a score of 0 (clear) to 1 (almost clear) at day 99 (final study visit) by acne PGA scoring system. Full PGA scale from 0-5, with lower score indicating better drug efficacy</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Severity</title>
        <description>Safety/drug-tolerance evaluated by subject-reported adverse events as well as physician evaluated erythema, scaling, drying, and stinging/burning on a 0-3 point scale, where 0=none and 3=severe.</description>
        <time_frame>Day 99</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combo</title>
            <description>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Severity</title>
          <description>Safety/drug-tolerance evaluated by subject-reported adverse events as well as physician evaluated erythema, scaling, drying, and stinging/burning on a 0-3 point scale, where 0=none and 3=severe.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>99 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lidamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combo</title>
          <description>lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anjali Vekaria</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-3288</phone>
      <email>anjali.shroff@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

